foscarnet has been researched along with Kaposi Sarcoma in 26 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Immunosuppressive therapy was reduced, and the patient was treated with foscarnet for 2 weeks, leading to a dramatic normalization of blood cell counts, concomitantly with the disappearance of HHV-8 viremia." | 7.71 | Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. ( Barozzi, P; Facchetti, F; Luppi, M; Rasini, V; Re, A; Riva, G; Rossi, G; Sandrini, S; Setti, G; Torelli, G, 2002) |
| " In this report we describe the effects of foscarnet on HHV-8 viremia in an HIV-infected patient with disseminated Kaposi s sarcoma and a presumably HHV-8 associated hemophagocytic syndrome." | 7.70 | Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. ( Fleckenstein, B; Harrer, T; Kalden, JR; Löw, P; Manger, B; Neipel, F; Rascu, A; Steininger, H, 1998) |
| " Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated." | 4.79 | Viral lesions of the mouth in HIV-infected patients. ( Itin, PH; Lautenschlager, S, 1997) |
| " Immunosuppressive therapy was reduced, and the patient was treated with foscarnet for 2 weeks, leading to a dramatic normalization of blood cell counts, concomitantly with the disappearance of HHV-8 viremia." | 3.71 | Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. ( Barozzi, P; Facchetti, F; Luppi, M; Rasini, V; Re, A; Riva, G; Rossi, G; Sandrini, S; Setti, G; Torelli, G, 2002) |
| "Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet." | 3.70 | Foscarnet decreases HIV-1 plasma load. ( Barbeau, P; Breilh, D; Denisi, R; Devianne-Garrigue, I; Dupon, M; Fleury, HJ; Leng, B; Pellegrin, I; Pellegrin, JL; Ragnaud, JM, 1998) |
| " In this report we describe the effects of foscarnet on HHV-8 viremia in an HIV-infected patient with disseminated Kaposi s sarcoma and a presumably HHV-8 associated hemophagocytic syndrome." | 3.70 | Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. ( Fleckenstein, B; Harrer, T; Kalden, JR; Löw, P; Manger, B; Neipel, F; Rascu, A; Steininger, H, 1998) |
| "PFA may be an effective therapy for AIDS-related KS; prospective trials are indicated." | 1.30 | Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. ( Gee, L; Jacobson, MA; Lugo, D; Robles, R, 1999) |
| "Foscarnet, an expensive treatment, has serious side effects, especially kidney toxicity." | 1.29 | Kaposi's sarcoma: possible Foscarnet treatment? ( James, JS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (80.77) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luppi, M | 1 |
| Barozzi, P | 1 |
| Rasini, V | 1 |
| Riva, G | 1 |
| Re, A | 1 |
| Rossi, G | 1 |
| Setti, G | 1 |
| Sandrini, S | 1 |
| Facchetti, F | 1 |
| Torelli, G | 1 |
| Brown, TJ | 1 |
| McCrary, M | 1 |
| Tyring, SK | 1 |
| Senanayake, S | 1 |
| Kelly, J | 1 |
| Lloyd, A | 1 |
| Waliuzzaman, Z | 1 |
| Goldstein, D | 1 |
| Rawlinson, W | 1 |
| Costagliola, D | 1 |
| Mary-Krause, M | 1 |
| Morfeldt, L | 1 |
| Torssander, J | 1 |
| Jones, JL | 2 |
| Hanson, DL | 2 |
| Chu, SY | 1 |
| Ward, JW | 1 |
| Jaffe, HW | 2 |
| Glesby, MJ | 1 |
| Hoover, DR | 1 |
| Weng, S | 1 |
| Graham, NM | 1 |
| Phair, JP | 1 |
| Detels, R | 1 |
| Ho, M | 1 |
| Saah, AJ | 1 |
| Humphrey, RW | 1 |
| O'Brien, TR | 1 |
| Newcomb, FM | 1 |
| Nishihara, H | 1 |
| Wyvill, KM | 1 |
| Ramos, GA | 1 |
| Saville, MW | 1 |
| Goedert, JJ | 1 |
| Straus, SE | 1 |
| Yarchoan, R | 1 |
| Larkin, M | 1 |
| Mocroft, A | 1 |
| Youle, M | 1 |
| Gazzard, B | 1 |
| Morcinek, J | 1 |
| Halai, R | 1 |
| Phillips, AN | 1 |
| Itin, PH | 1 |
| Lautenschlager, S | 1 |
| Grose, C | 1 |
| Kedes, DH | 1 |
| Ganem, D | 1 |
| Medveczky, MM | 1 |
| Horvath, E | 1 |
| Lund, T | 1 |
| Medveczky, PG | 1 |
| Cordero, E | 1 |
| López-Cortés, LF | 1 |
| Viciana, P | 1 |
| Alarcón, A | 1 |
| Pachón, J | 1 |
| Devianne-Garrigue, I | 1 |
| Pellegrin, I | 1 |
| Denisi, R | 1 |
| Dupon, M | 1 |
| Ragnaud, JM | 1 |
| Barbeau, P | 1 |
| Breilh, D | 1 |
| Leng, B | 1 |
| Fleury, HJ | 1 |
| Pellegrin, JL | 1 |
| Löw, P | 1 |
| Neipel, F | 1 |
| Rascu, A | 1 |
| Steininger, H | 1 |
| Manger, B | 1 |
| Fleckenstein, B | 1 |
| Kalden, JR | 1 |
| Harrer, T | 1 |
| Boivin, G | 1 |
| Gaudreau, A | 1 |
| Toma, E | 1 |
| Lalonde, R | 1 |
| Routy, JP | 1 |
| Murray, G | 1 |
| Handfield, J | 1 |
| Bergeron, MG | 1 |
| Robles, R | 1 |
| Lugo, D | 1 |
| Gee, L | 1 |
| Jacobson, MA | 1 |
| Rabkin, CS | 1 |
| Testa, MA | 1 |
| Huang, J | 1 |
| Von Roenn, JH | 1 |
| Willers, CP | 1 |
| Reimann, G | 1 |
| Mertins, L | 1 |
| Brockmeyer, NH | 1 |
| Dworkin, MS | 1 |
| Roos, TC | 1 |
| Albrecht, H | 1 |
| James, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE II PROTOCOL WITH LABORATORY CORRELATES OF 1-[(S)-3-HYDROXY-2-(PHOSPHOMETHOXY)PROPYL]CYTOSINE DIHYDRATE(CIDOFOVIR) IN PATIENTS WITH KAPOSI'S SARCOMA (KS)[NCT00019240] | Phase 2 | 0 participants | Interventional | 1996-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for foscarnet and Kaposi Sarcoma
| Article | Year |
|---|---|
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
Viral lesions of the mouth in HIV-infected patients.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cytomegalovirus In | 1997 |
Childhood infections with human herpesviruses types 6, 7, and 8.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antiviral Agents; Burkitt Lymphoma; Central Nervous | 1996 |
2 trials available for foscarnet and Kaposi Sarcoma
| Article | Year |
|---|---|
Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Bisexuality; Case-Control Studie | 1996 |
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
Topics: Acyclovir; Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Female; Follow-Up Studies | 1996 |
21 other studies available for foscarnet and Kaposi Sarcoma
| Article | Year |
|---|---|
Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet.
Topics: Antiviral Agents; DNA, Viral; Foscarnet; Herpesvirus 8, Human; Humans; Kidney Transplantation; Male; | 2002 |
Multicentric Castleman's disease treated with antivirals and immunosuppressants.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antiviral Agents; Castleman Disea | 2003 |
Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Bias; Female; Follow-Up Studies; | 1995 |
Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients.
Topics: Adult; Foscarnet; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Palatal Neoplasms; | 1994 |
AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Opportunistic Infections; Female; Foscar | 1995 |
Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Base Sequence; Blood Coagulation Disord | 1996 |
Some antivirals may lower Kaposi's sarcoma risk.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Ganciclovir; Humans; Sarcoma, Kapos | 1996 |
Isolation of new transmissible herpesvirus suggests additional therapeutic approaches for KS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; DNA, Viral; Foscarnet; Herpesviridae; Herpesvi | 1996 |
Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytosine; DNA Probes; DNA, Viral; Foscarnet; Ganciclovir; He | 1997 |
In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
Topics: Acyclovir; Antiviral Agents; Carcinogens; Cidofovir; Cytosine; DNA-Directed DNA Polymerase; DNA, Vir | 1997 |
Foscarnet and AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Foscarnet; Humans; Male; Sarcoma, Kapos | 1997 |
Foscarnet decreases HIV-1 plasma load.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Femal | 1998 |
Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Foscarnet; Herpesvirus 8 | 1998 |
Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 1999 |
Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1999 |
Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; | 1999 |
Influence of foscarnet on HIV-associated Kaposi's sarcoma derived cell lines.
Topics: Antiviral Agents; Cell Division; Fibroblasts; Foscarnet; Herpesvirus 8, Human; HIV Infections; Human | 1999 |
Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Drug Therapy, Combination; | 2000 |
Foscarnet-associated eosinophilic folliculitis in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Eosinophils; Folliculitis; Foscarnet; Humans; Male; Rever | 2001 |
Kaposi's sarcoma: possible Foscarnet treatment?
Topics: Foscarnet; HIV Infections; Humans; Sarcoma, Kaposi | 1995 |
Herpesvirus treatment for KS.
Topics: Antiviral Agents; Eligibility Determination; Foscarnet; Herpesviridae Infections; Humans; Sarcoma, K | 1995 |